Hematology is in our blood

Boule Diagnostics AB is a company with a strong heritage when it comes to hematology diagnostics. We developed the very first European blood cell counter, and today our instruments, reagents, calibrators and controls are used by healthcare providers around the world. Boule’s products are currently on sale in more than 100 countries.

Our blood tests help provide one of the first and most important indicators of a disease state and Boule systems play an increasingly important role in helping build the infrastructure of healthcare for small and medium size patient care environments in both human and veterinary markets.

Boule is listed on NASDAQ Stockholm since June 2011.

Interview (in Swedish) with Boules CEO Ernst Westman answers questions about why sales fell in 2015, the potential clinical chemistry, the implications of the recent cooperation agreements and prospects facing in 2016.

.

Financial Calendar

Quarterly report second quarter 2016
2016-08-01

Quarterly report third quarter 2016
2016-11-09

Year-end report
2017-02-16

Annual General Meeting
2017-05-11

Quarterly report first quarter 2017
2017-05-11

Quarterly report second quarter 2017
2017-07-31

Quarterly report third quarter 2017
2017-11-08

Event

Welcome to visit us at Medica 2016

med1601_tm20_cmyk01

14-17 November, Düsseldorf, Germany

Company in figures 2015

0

Net sales, SEK million
(increased by 8%)

0

Operating margin
(increased by 19%)

0 %

Gross margin
(increased by 1%)

0 %

Equity/assets ratio
(increased by 1%)